Relmada Therapeutics Inc. (NASDAQ:RLMD)
Old Forum Content for RLMD
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- bb_b: $RLMD still holding up
- jvee: @bb_b $RLMD How did you come upon this stock? My son-in-law just hired on.
- bb_b: $rlmd new high
- veghead: @bb_b $rlmd Nice !
- bb_b: $RLMD hitting downward sloping trend line
- woodman: @bRobert $SUPN - It does have that bR flare. $RLMD is another with turnaround potential. At descending resistance now. Need to watch and see how it plays out.
- Reif99: $RLMD breakout on strong volume, earnings AMC today.
- scottrades: @Herb $RH $RLMD Hey Herb, sorry I missed that one. RLMD is in a nice uptrend. Look for a pullback above 39.18
- Herb: @scottrades $RH Another I asked about was $RLMD. np.
- WebstreamDyn: BIOs gone wild! $KOD, $RLMD, $AUPH, $ALLK and i missed them all while out of the office working. :-(
- Herb: @WebstreamDyn $KOD $RLMD $AUPH $ALLK Was RLMD an ipo today?
- WebstreamDyn: @WebstreamDyn $KOD $RLMD $AUPH $ALLK BIOs I am watching.. $AMRN, $ARWR, $ASLN, $CLVS ....any other BIOs to watch? (Also, watching SMM tweets. :-) )
- WebstreamDyn: @Herb $KOD $RLMD $AUPH $ALLK This is all I know... >>> NEW YORK , Oct. 8, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMDD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company's common stock has been approved for listing on The Nasdaq Capital Market . Trading on Nasdaq is expected to begin on Thursday, October 10 , under the existing symbol, "RLMD." <<<
| Stock Price | $4.00 |
| Change | -6.98% |
| Volume | 152,611 |
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of proven drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The product portfolio of the company includes d-Methadone, an N-methyl-D-aspartate receptor antagonist for treating depression and neuropathic pain; LevoCap ER, an abuse-resistant, the dosage form of the opioid analgesic levorphanol; BuTab an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Its lead product d-Methadone is an oral agent for the treatment of depression, pain, and other potential conditions affecting the brain functions.
Request Video of RLMDAlready a member? Sign in here.
Past Month
Leading Peers
-
$7.93 55.33%
-
$6.46 52.02%
-
$6.99 31.72%
Past Month
Lagging Peers
-
$8.70 -37.20%
-
$12.95 -23.01%
-
$10.62 -20.14%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!